Using AMG900 to Treat Breast Cancer
Richard S. Finn, MD, discusses the aurora kinase inhibitor AMG900.
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the aurora kinase inhibitor AMG900.
Clinical Pearls
- AMG900 is a small molecule inhibitor of aurora kinases, which are proteins that are involved in maintaining DNA integrity and controlling DNA replication
- AMG900 has been evaluated in breast cancer models to try to determine which group of patients will benefit
- Results of an AMG900 trial showed that patients with p53 mutation may have a potential benefit with the agent
- p53 mutations are common throughout all the molecular subtypes of breast cancer but triple-negative breast cancer (TNBC) shows a higher frequency of these mutations
- This early preclinical work suggests that p53 mutations may act as a biomarker for selecting patients who will benefit from AMG900
- AMG900 is now in a phase I study that includes patients with TNBC and a biomarker component will be included in the study to help researchers get a better understanding of how the drug is working
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
January 15th 2025CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.
Read More
Durability and Intracranial Efficacy Observed With T-DXd in HER2+ MBC
January 13th 2025During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed how the outcomes of the DESTINY-Breast03 and other trials impact treatment of metastatic HER2-positive breast cancer in the second article of a 2-part series.
Read More
